Mylan N.V. just released its latest quarterly financial results, posting adjusted earnings of $1.43 per share and revenues of $3.24 billion.
Currently, MYL is a Zacks Rank #3 (Hold), but that could change based on today’s results. The stock is currently up 1.4% to $40.89 per share in after-hours trading shortly after its earnings report was released.
Mylan:
Beat earnings estimates. The company posted adjusted earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.41 per share.
Missed revenue estimates. The company saw revenue figures of $3.24 billion, beating our consensus estimate of $3.27 billion.
Total revenues were down 1% from the prior-year quarter. North American third party net sales were down 17%. Excluding the decrease in sales of the EpiPen, this segment slumped 8%. Europe segment third party net sales were $1.07 billion, up 16%.
“Mylan's business continues to deliver solid results and I am pleased once again to provide a strong outlook for growth, especially given the U.S. environment,” said CEO Heather Bresch. “Our performance is a testament to the strength, diversification and resilience of our unique global platform, and it demonstrates that Mylan truly is built to last.”
Mylan said that it expects full-year 2018 revenues to fall in the range of $11.75 billion to $13.25 billion. Our current consensus estimate is calling for revenues of $12.64 billion for the year.
Here’s a graph that looks at Mylan’s recent earnings performance:
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals.
Check back later for our full analysis on MYL’s earnings report!
Want more analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Image: Bigstock
Mylan (MYL) Posts Earnings Beat, In-Line Guidance
Mylan N.V. just released its latest quarterly financial results, posting adjusted earnings of $1.43 per share and revenues of $3.24 billion.
Currently, MYL is a Zacks Rank #3 (Hold), but that could change based on today’s results. The stock is currently up 1.4% to $40.89 per share in after-hours trading shortly after its earnings report was released.
Mylan:
Beat earnings estimates. The company posted adjusted earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.41 per share.
Missed revenue estimates. The company saw revenue figures of $3.24 billion, beating our consensus estimate of $3.27 billion.
Total revenues were down 1% from the prior-year quarter. North American third party net sales were down 17%. Excluding the decrease in sales of the EpiPen, this segment slumped 8%. Europe segment third party net sales were $1.07 billion, up 16%.
“Mylan's business continues to deliver solid results and I am pleased once again to provide a strong outlook for growth, especially given the U.S. environment,” said CEO Heather Bresch. “Our performance is a testament to the strength, diversification and resilience of our unique global platform, and it demonstrates that Mylan truly is built to last.”
Mylan said that it expects full-year 2018 revenues to fall in the range of $11.75 billion to $13.25 billion. Our current consensus estimate is calling for revenues of $12.64 billion for the year.
Here’s a graph that looks at Mylan’s recent earnings performance:
Mylan N.V. Price, Consensus and EPS Surprise
Mylan N.V. Price, Consensus and EPS Surprise | Mylan N.V. Quote
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals.
Check back later for our full analysis on MYL’s earnings report!
Want more analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>